High-efficiency neutralizing epitope located in stem helix region of S2 subunit of new coronavirus and potential application of high-efficiency neutralizing epitope

By developing broad-spectrum neutralizing nano-antibody H17 and H145 targeting the SARS-CoV-2S2 subunit, the problem of insufficient neutralization of existing antibodies against Omickron sub-sector strains was solved, and SARS-CoV was achieved -2 and efficient neutralization of sabevirus provides new prevention and treatment options.

CN118909056APending Publication Date: 2024-11-08SICHUAN UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410765929.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-02-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing monoclonal antibody drugs have poor neutralization of the Omickron Asia strain of the new coronavirus, and the vaccine is not ideal in preventing viral infections, which leads to challenges in the prevention and treatment of the new coronavirus, especially for SARS-CoV- Neutralizing antibodies to the 2S2 subunit have not been developed.

Method used

Develop broad-spectrum neutralizing nano-antibody H17 and H145 targeting the SARS-CoV-2S2 subunit, and verify its specific binding ability and neutralization activity through ELISA, flow cytometry experiments and pseudovirus neutralization experiments, and bind SARS-CoV -2S2 protein epitope peptide is used to prepare vaccines.

Benefits of technology

H17 and H145 nano-antibodies showed high affinity and broad-spectrum neutralization activities for SARS-CoV-2 original strains and variant strains, sabevirus, which can effectively inhibit virus membrane fusion, and the binding epitope is not affected by pH acidification, providing New prevention and treatment options were made.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909056A_ABST
    Figure CN118909056A_ABST
Patent Text Reader

Abstract

The invention discloses a high-efficiency neutralizing epitope located in a stem helix region of a new coronavirus S2 subunit and potential application of the high-efficiency neutralizing epitope, and belongs to the field of biological medicines. The invention discloses two broad-spectrum neutralizing nano antibodies H17 and H145 capable of effectively inhibiting invasion of an SARS-CoV-2 original strain, a variant of the SARS-CoV-2 original strain and a sand shell virus, a targeted antigen epitope amino acid sequence D1139PLQPELDSFKEEL1152 is highly conserved in the variant and various sand shell viruses, and it is indicated that the neutralizing effect of the broad-spectrum neutralizing nano antibodies H17 and H145 may not be affected by virus mutation. And the method has a better neutralizing effect on the sand shell virus possibly appearing in the future. In addition, the window period for playing the inhibitory activity is obviously superior to that of reported neutralizing nano antibodies R150 and Nb20 targeting RBD, and it is prompted that the nano antibodies possibly have a better treatment effect. Therefore, the broad-spectrum neutralizing nano antibody H17 and H145 can become a novel tool for detecting, preventing and treating SARS-CoV-2 virus infection.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with application number CN202310114058.8, application date February 11, 2023, and invention name “Two broad-spectrum neutralizing nanoantibodies targeting the stem helix epitope of the S2 subunit of the new coronavirus and their potential applications”. Technical Field

[0002] The present invention relates to a highly effective neutralizing epitope located in the stem helix region of the S2 subunit of the novel coronavirus and its potential application, and belongs to the field of biomedicine. Background Art

[0003] The novel coronavirus is the most extensive global pandemic faced by human history, which has brought great impact to human society. Due to the continuous evolution and mutation of the virus, the variants are rapidly updated and iterated, especially the recently popular strains of the Omicron sublineage, which makes most of the existing monoclonal antibody drugs lose their antiviral efficacy due to neutralization escape, and also causes frequent breakthrough infections in the population vaccinated with existing vaccines, which brings new challenges to the prevention and treatment of the novel coronavirus. Therefore, it is urgent to develop broad-spectrum antiviral drugs or vaccines to cope with the prevalence of novel coronavirus variants.

[0004] SARS-CoV-2 belongs to the genus Betacoronavirus and is a single-stranded positive-sense RNA virus wrapped in an envelope. The surface of the virus particle is composed of uniformly distributed homotrimeric spike proteins (S), which mediate the virus's invasion of host cells and are the main targets for neutralizing antibodies and vaccine design [1,2]. The SARS-CoV-2 S protein is a type I transmembrane protein composed of two subunits, S1 and S2, which are responsible for the adhesion and fusion of the virus with the target cell, respectively. Among them, the S1 subunit contains a receptor binding domain (RBD), whose main function is to bind to the host cell surface receptor protein angiotensin converting enzyme 2 (ACE2), which is the gateway for the virus to infect cells [3,4]. The RBD subunit is currently a popular target for most neutralizing antibodies and vaccine designs. However, due to the evolution of the virus and the emergence of mutant strains, multiple key sites in the RBD region have mutated, especially the recently popular Omicron sublineage strain, which binds more tightly to the ACE2 receptor, making the virus more likely to infect and invade human cells. The accumulation and enrichment of a large number of amino acid mutations in the RBD region in the Omicron sublineage strain has led to the immune escape of a large number of neutralizing antibodies targeting the RBD [5-7].

[0005] The SARS-CoV-2 S2 subunit is responsible for mediating the fusion process between the viral envelope and the cell membrane, so it is also called the fusion subunit. When the spike protein binds to the cell receptor ACE2, it induces the dissociation of the S1 subunit, the fusion peptide is exposed and inserted into the target cell membrane, and the heptad repeat 1 (HR1) forms a long central triple helix structure. The heptad repeat 2 (HR2) also forms a helical structure and binds in an antiparallel manner to the groove formed by two adjacent HR1s to form a six-helix cluster fusion core, which ultimately drives the fusion of the viral envelope and the target cell membrane [8,9]. In sharp contrast to the accumulation and enrichment of many mutations in the RBD region of the SARS-CoV-2 virus in mutants, the sequence and structure of the S2 fusion core of the SARS-CoV-2 virus are highly conserved in evolution. Therefore, neutralizing antibodies or inhibitory drugs targeting the SARS-CoV-2 fusion core can achieve broad-spectrum antiviral therapeutic effects and will not be escaped by viral mutants.

[0006] Sarbecovirus is a subgenus of the genus Betacoronavirus, which includes SARS-CoV-2, severe acute respiratory syndrome coronavirus (SARS-CoV), and animal-derived coronaviruses such as RANG / GD, WIV1, and HKU3 that have similar characteristics to SARS-CoV-2 and are isolated from bats, pangolins, and civets. These viruses may also cause cross-species transmission and potential pandemics [10,11]. Fortunately, the S2 subunit of SARS-CoV-2 and other sarbecoviruses is also highly conserved in sequence and structure, which means that the S2 fusion subunit is an ideal target for the development of antiviral drugs and vaccine design to combat the spread of sarbecoviruses.

[0007] Nanobodies are single-domain antibodies found in camelids or cartilaginous fish that contain only one heavy chain variable region, also known as VHH. They are the smallest antibody fragments known to bind to target antigens

[12] . Nanobodies have the same structural stability and antigen-binding activity as heavy chain antibodies, and have the dual advantages of traditional antibodies and small molecule drugs, such as small molecular weight, easy penetration of the blood-brain barrier, high expression and low cost, strong specificity, high affinity, weak immunogenicity, stable properties and short development cycle

[13] . Studies have reported that the neutralizing nanobodies R150

[14] and Nb20

[15] targeting SARS-CoV-2 RBD both exert neutralizing activity by competing for the binding between ACE2 and RBD. However, there are no reports of broad-spectrum neutralizing nanobodies targeting the S2 fusion subunit. Therefore, at this stage, there is an urgent need to develop broad-spectrum neutralizing nanobodies targeting the S2 fusion subunit to provide new drug options for the prevention or treatment of new coronavirus and its variants or possible future sab virus infections.

[0008] 1.Ngoepe,MP,KCTapala,and HSClayton,Prophylactic and TherapeuticPotential Zinc MetallodrugsDrug Discovery:Identification of SARS-CoV-2Replication and Spike / ACE2 Inhibitors.Curr Comput

[0009] Aided Drug Des,2022.18(7):p.519-534.

[0010] 2.Turonova,B.,et al.,In situ structural analysis of SARS-CoV-2 spikereveals flexibility mediated by three

[0011] hinges.Science,2020.370(6513):p.203-208.

[0012] 3.Lan,J.,et al.,Structure of the SARS-CoV-2spike receptor-bindingdomain bound to the ACE2 receptor.

[0013] Nature,2020.581(7807):p.215-220.

[0014] 4.Letko,M.,A.Marzi,and V.Munster,Functional assessment of cell entryand receptor usage for

[0015] SARS-CoV-2and other lineage B betacoronaviruses.Nat Microbiol,2020.5(4):p.562-569.

[0016] 5.Wang,Q.,et al.,Alarming antibody evasion properties of rising SARS-CoV-2BQ and XBB subvariants.

[0017] Cell,2022.

[0018] 6.Cao,Y.,et al.,Imprinted SARS-CoV-2humoral immunity inducesconvergent Omicron RBD evolution.

[0019] Nature,2022.

[0020] 7.Chen,R.E.,et al.,Resistance of SARS-CoV-2variants to neutralizationby monoclonal and serum-derivedpolyclonal antibodies.Nat Med,2021.27(4):p.717-726.

[0021] 8.Cai,Y.,et al.,Distinct conformational states of SARS-CoV-2spikeprotein.Science,2020.369(6511):p.1586-1592.

[0023] 9.Fan,X.,et al.,Cryo-EM analysis of the post-fusion structure of theSARS-CoV spike glycoprotein.Nat

[0024] Commun,2020.11(1):p.3618.

[0025] 10.Lam,T.T.,et al.,Identifying SARS-CoV-2-related coronaviruses inMalayan pangolins.Nature,2020.

[0026] 583(7815):p.282-285.

[0027] 11.Xiao,K.,et al.,Isolation of SARS-CoV-2-related coronavirus fromMalayan pangolins.Nature,2020.

[0028] 583(7815):p.286-289.

[0029] 12.Muyldermans,S.,Nanobodies:natural single-domain antibodies.AnnuRev Biochem,2013.82:p.775-97.

[0031] 13.Vanlandschoot,P.,et al.,Nanobodies(R):new ammunition to battleviruses.Antiviral Res,2011.92(3):p.389-407.

[0033] 14.Yang,J.,et al.,A Potent Neutralizing Nanobody Targeting the SpikeReceptor-Binding Domain of

[0034] SARS-CoV-2and the Structural Basis of Its Intimate Binding.FrontImmunol,2022.13:p.820336.

[0035] 15. Xiang, Y., et al., Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science, 2020.370(6523): p.1479-1484. Summary of the invention

[0037] Almost all the monoclonal antibody drugs currently on the market have no significant neutralizing and antiviral effects on the Omicron sublineage strains that are currently prevalent, nor do they have obvious preventive effects. In addition, although vaccination can reduce the incidence of severe COVID-19, it is not ideal in preventing viral infection, which brings new challenges to the prevention and treatment of COVID-19. Therefore, it is urgent to develop broad-spectrum antiviral drugs or vaccines to respond to the spread of COVID-19 variants.

[0038] The present invention verifies the specific binding ability of nano antibodies to SARS-CoV-2S2 (T1076-Q1208) antigens by ELISA and flow cytometry experiments, and screens out the nano antibodies H17 (amino acid sequence as SEQ ID NO.22, nucleotide sequence as SEQ ID NO.31) and H145 (amino acid sequence as SEQ ID NO.23, nucleotide sequence as SEQ ID NO.32) with the best inhibitory effect by syncytium formation inhibition experiments. Then, the inhibitory activity of H17 and H145 on membrane fusion mediated by the S protein of the original strain of SARS-CoV-2 is verified by the syncytium formation inhibition experiment, and the inhibitory activity of H17 and H145 on the original strain and variant strain (especially the Omicron sublineage) of SARS-CoV-2 pseudovirus is verified by the pseudovirus neutralization experiment, proving that H17 and H145 have pan-variant neutralizing activity. At the same time, the antigenic epitopes bound by H17 and H145 are verified by WB, ELISA and BLI experiments, and their shortest epitope amino acid sequences are all D 1139 PLQPELDSFKEEL 1152 , located in the stem helix (SH) region of the S2 subunit of SARS-CoV-2. Sequence analysis revealed that D 1139 PLQPELDSFKEEL 1152The amino acid sequences of SARS-CoV-2, SARS-CoV, PANG / GD, WIV1 and HKU3 of the Sabeivirus genus are highly conserved, and flow cytometry and pseudovirus neutralization experiments have verified that H17 and H145 have high affinity and broad-spectrum neutralizing activity against the above Sabeiviruses. Subsequently, the BLI technology was used to verify that pH acidification had no significant effect on the affinity of H17 and H145 to the SARS-CoV-2 S protein antigenic epitope, indicating that when the virus infects the target cells through the endosome pathway, the nanoantibodies H17 and H145 can still exert good inhibitory activity. Finally, flow cytometry experiments verified that H17 and H145 bind to the S protein in the pre-fusion conformation with high affinity; and the syncytium formation inhibition experiment proved that the window time for H17 and H145 to exert inhibitory activity is significantly better than that of antibodies that exert inhibitory activity by competing for ACE2 and RBD binding, such as R150 and Nb20, providing important data for the use of H17 and H145 in the prevention and treatment of SARS-CoV-2 virus infection.

[0039] The present invention provides a broad-spectrum nanobody against Sarbecoviruses, wherein the broad-spectrum nanobody comprises H17 or H145; CDR1, CDR2 and CDR3 of the heavy chain variable region of H17 respectively have the amino acid sequences of SEQ ID NOs: 24-26; CDR1, CDR2 and CDR3 of the heavy chain variable region of H145 respectively have the amino acid sequences of SEQ ID NOs: 24, 25 and 27.

[0040] In one embodiment, the amino acid sequence of the broad-spectrum nanobody is shown as SEQ ID NO.22 or SEQ ID NO.23.

[0041] The present invention provides a gene encoding the above broad-spectrum nanobody.

[0042] In one embodiment, the nucleotide sequence of the gene encoding the above-mentioned broad-spectrum nanobody is shown as SEQ ID NO.31 or SEQ ID NO.32.

[0043] The present invention provides a vector and a host cell carrying the gene.

[0044] In one embodiment, the host cell is a host cell for expressing foreign proteins.

[0045] In one embodiment, the host cell is a bacterial, yeast, insect cell or a mammalian cell.

[0046] The present invention provides a pharmaceutical composition, which contains the above-mentioned broad-spectrum nanobody.

[0047] In one embodiment, the pharmaceutical composition further contains a pharmaceutically acceptable excipient.

[0048] In one embodiment, the excipients include a binder, a filler, a disintegrant, a lubricant, a preservative, an antioxidant, a flavoring agent, an aromatic agent, a solubilizer, an emulsifier, a solubilizer, an osmotic pressure regulator, and a colorant.

[0049] The present invention provides the use of the broad-spectrum nanobody in preparing products for treating, preventing, detecting or diagnosing Sabei virus.

[0050] In one embodiment, the product comprises a drug, a detection reagent, a detection kit, or an in vivo imaging probe.

[0051] In one embodiment, the Sabeivirus includes PANG / GD, SARS-CoV, WIV1, HKU3 and SARS-CoV-2.

[0052] In one embodiment, the SARS-CoV-2 variant strains include Omicron (BA.1, BA.2, BA.2.12.1, BA.4 / 5), Beta (B.1.351), Mu (B.1.621), Kappa (B.1.617.1), and Delta (B.1.617.2).

[0053] In one embodiment, the use is not for the purpose of diagnosis or treatment of a disease.

[0054] The present invention provides a SARS-CoV-2S2 protein epitope peptide, the amino acid sequence of the epitope peptide is shown in SEQ ID NO.28.

[0055] The present invention provides a gene encoding the above-mentioned SARS-CoV-2S2 protein epitope peptide.

[0056] In one embodiment, the nucleotide sequence of the gene encoding the above-mentioned SARS-CoV-2S2 protein epitope peptide is shown as SEQ ID NO.34.

[0057] The present invention provides an expression vector or a host cell containing a gene encoding the above-mentioned SARS-CoV-2S2 protein epitope peptide.

[0058] The present invention provides a broad-spectrum vaccine against coronavirus, which contains the above-mentioned SARS-CoV-2S2 protein epitope peptide, or the above-mentioned gene, or the above-mentioned expression vector or the above-mentioned host cell.

[0059] In one embodiment, the broad-spectrum vaccine further comprises an immunologically acceptable carrier or adjuvant.

[0060] The present invention provides the use of the above-mentioned SARS-CoV-2S2 protein epitope peptide or the above-mentioned gene or the above-mentioned expression vector or the above-mentioned host cell in the preparation of a broad-spectrum coronavirus vaccine, an antigen detection kit, a SARS-CoV-2S2 protein monoclonal antibody or a bispecific antibody.

[0061] Beneficial effects:

[0062] (1) The present invention successfully screened two broad-spectrum nano-neutralizing antibodies targeting S2, which have strong inhibitory activity against the original strain of SARS-CoV-2, the variant strain of SARS-CoV-2 and various species of Sabeivirus, respectively named H17 and H145. The present invention proves that H17 and H145 can bind to the S protein of the virus before fusion with high affinity, and the binding affinity is not affected by pH acidification of the endosome pathway; it also verifies that H17 and H145 can still exert a good inhibitory effect when used after membrane fusion occurs. The nano-antibodies H17 and H145 in the present invention can be used to prepare the prevention and / or treatment of infection with the original strain or variant strain of the new coronavirus, and can also be used to prepare drugs for the prevention or treatment of other Sabeivirus infections.

[0063] (2) The present invention also successfully identified the precise antigen binding epitope amino acid sequences of two neutralizing nanobodies on the viral S protein, which are D 1139 PLQPELDSFKEEL 1152 , which is located in the stem helix structure of the SARS-CoV-2 S2 subunit, indicating that H17 and H145 can exert antiviral neutralization effects by inhibiting conformational changes in membrane fusion. 1139 PLQPELDSFKEEL 1152 It can be used as a target for the design of a broad-spectrum neutralizing vaccine, and also provide a preventive and / or therapeutic strategy for preventing or treating new variants and Sabei virus infections that may emerge in the future. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 : SARS-CoV-2S2 (T1076-Q1208) trimer protein purification molecular sieve and SDS-PAGE. The middle line of the molecular sieve figure is the absorption value at 280nm. Figure 1 a: The molecular sieve image shows S2" (T1076-Q1208) trimer protein, and the SDS-PAGE shows the S2" (T1076-Q1208) protein corresponding to the molecular sieve peak position. Figure 1 b: Molecular sieve diagram of S2 (T1076-Q1208) multimeric protein after PSP digestion, lane 1 corresponds to S2 (T1076-Q1208) protein, and lane 2 corresponds to GST protein.

[0065] Figure 2:Gel filtration chromatography and SDS-PAGE analysis of nanobodies. The middle line of the molecular sieve diagram is the absorption value at 280nm. The molecular sieve diagram is the molecular sieve peak diagram is the nanobody peak, and SDS-PAGE respectively indicates the purity of the nanobody in the corresponding diagram.

[0066] Figure 3 : ELISA experiment verifies the binding of nanoantibodies to SARS-CoV-2S2' (T1076-Q1208) antigen. Red and blue represent nanoantibody concentrations of 200nM and 1000nM, respectively. The ordinate is the absorbance value at 450nm (OD450).

[0067] Figure 4 :Flow cytometry experiments verify the ability of nanobodies to bind to SARS-CoV-2S protein on the cell surface. Red and blue represent nanobody concentrations of 200nM and 1000nM, respectively. The horizontal axis represents 20 nanobodies. The vertical axis is the percentage of 293T-S cells that bind to nanobodies.

[0068] Figure 5 : Results of nanoantibodies inhibiting SARS-CoV-2 S protein-mediated syncytium formation. NC: 293T-S / EGFP cells only; PC: 293T-S / EGFP combined with 293T-ACE2 cells, PBS as nanoantibody control group. The scale bar represents 100 μm. White arrows represent significantly formed syncytia.

[0069] Figure 6 : The SARS-CoV-2S protein-mediated syncytium formation inhibition experiment detected the inhibitory activity of nanoantibodies H17 and H145. The horizontal axis is the nanoantibody concentration, and the vertical axis is the inhibitory activity of the nanoantibody on syncytium formation.

[0070] Figure 7 : Pseudovirus neutralization curves of nanoantibodies H17 and H145 against the original strain of SARS-CoV-2. The horizontal axis is the concentration of nanoantibodies, the vertical axis is the neutralization rate, and the nanoantibody H6 is used as a negative control.

[0071] Figure 8 : Neutralization activity of nanoantibodies H17 and H145 against SARS-CoV-2 variant pseudovirus. The horizontal axis is the concentration of nanoantibodies, the vertical axis is the neutralization rate, and nanoantibody H6 is used as a negative control.

[0072] Fig. 9 : Identification of antigen-binding epitopes for neutralizing nanobodies H17 and H145. Fig. 9 b, f, j: Western blotting experiments to identify the antigen-binding epitopes of H17 and H145; Fig. 9c, g, k: ELISA experiments to identify the antigen binding epitopes of H17 and H145. The horizontal axis is the concentration of H17 and H145 antibodies, and the vertical axis is the absorbance value at 450 nm (OD450). Fig. 9 d, h, l: BLI experiments to determine the binding kinetics of H17 or H145 with S2 (T1076-Q1208) proteins with different truncated lengths and GST tags at the N-terminus. The horizontal axis is the binding and dissociation time in seconds; the vertical axis is the binding response intensity on the probe surface in nm. Fig. 9 a, e, i: summary of the above experimental results, b represents binding, nb represents no binding.

[0073] Fig.10 :Nanoantibodies H17 and H145 antigen binding epitope D 1139 PLQPELDSFKEEL 1152 Comparison results of amino acid sequences among SARS-CoV-2 variants.

[0074] Fig.11 : Detection of broad-spectrum neutralizing activity of nanoantibodies H17 and H145 against Sabei virus. Fig.11 a: Comparison of amino acid sequences of several representative Sabei viruses SARS-CoV-2S2 (T1076-Q1208). The asterisk indicates the amino acid sequence of the shortest antigen binding epitope of H17 and H145. Fig.11 b: Flow cytometry assay to detect the affinity of H17 and H145 to the intact Sabei virus S protein on the cell surface. The horizontal axis is the concentration of nanoantibodies, and the vertical axis is the percentage of 293T-S cells that bind to the nanoantibodies. Fig.11 c: Pseudovirus neutralization experiment to detect the neutralization activity of H17 and H145 against Sabei virus. The horizontal axis is the concentration of nanoantibodies, the vertical axis is the neutralization rate, and the nanoantibody H6 is used as a negative control.

[0075] Fig.12 : BLI experiment determined the binding kinetics curve of H17 or H145 with S2" (T1076-Q1208) protein under pH 7.4, 6.0, and 5.4. The horizontal axis is the binding dissociation time, in seconds; the vertical axis is the binding response intensity on the probe surface, in nm; the curve represents nanoantibodies of different dilution concentrations, in nM.

[0076] Fig.13 : Flow cytometry assay to detect the affinity of H17 and H145 to the cell surface wild-type S protein and pre-fusion conformation S protein. The horizontal axis is the concentration of nanoantibodies, and the vertical axis is the percentage of 293T-S cells that bind to nanoantibodies.

[0077] Fig.14 :The syncytium formation inhibition experiment explored the inhibitory effect of nanobodies at different binding times. Pre represents that the nanobodies were added to 293T-ACE2 cells 1 hour after binding to 293T-S / EGFP cells; Co represents that the nanobodies were added to 293T-ACE2 cells at the same time after binding to 293T-S / EGFP cells; Post represents that the nanobodies were added 1 hour after binding to 293T-S / EGFP cells and 293T-ACE2 cells. DETAILED DESCRIPTION

[0078] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0079] pGEX-6P-1-GST vector: pGEX-6P-1 was used as the vector, and the DNA sequence encoding the GST recombinant protein and the PSP restriction site was added to the vector through the Nde I and Bam HI restriction sites (the nucleotide sequence is shown in SEQ ID NO.29).

[0080] Example 1 Expression and purification of SARS-CoV-2S2 (T1076-Q1208)

[0081] (1) Plasmid construction

[0082] (a) Through structural analysis, in order to obtain the stably expressed S2 (T1076-Q1208) antigen, the DNA fragment of S2 (T1076-Q1208) encoding the SARS-CoV-2 S protein (GenBank No. MN908947.3) (the nucleotide sequence is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2) was ligated into the pGEX-6P-1-GST vector using the Bam HI and Xho I restriction sites, and a foldon tag was inserted after the S2 (T1076-Q1208) fragment, and linked with a GS linker, and a 6×His tag and a translation stop codon were connected after the foldon tag. A recombinant protein with a GST tag at the N-terminus and a folden tag and a 6×His tag connected by a GS linker at the C-terminus was obtained (the amino acid sequence is shown in SEQ ID NO.35), which was named S2”(T1076-Q1208), and the recombinant plasmid was named GST-S2(T1076-Q1208)-folden-His. The S2”(T1076-Q1208) protein was purified after the GST tag was removed by PSP enzyme cleavage and the obtained S2(T1076-Q1208)-folden-His protein was named S2(T1076-Q1208).

[0083] (b) In the functional experiment, since the folden tag is not needed to stabilize the trimer structure of the protein and the His tag is not used to interfere with the experiment, a series of SARS-CoV-2S2 (T1076-Q1208) antigen protein truncations with different truncation lengths were designed, and a GST tag was attached to the N-terminus to help protein expression. First, the DNA fragment encoding S2 (T1076-Q1208) was connected to the pGEX-6P-1-GST tag vector to obtain a recombinant plasmid expressing the S2 (T1076-Q1208) fusion protein S2' (T1076-Q1208) with a GST tag attached to the N-terminus, named S2' (T1076-Q1208). As above, the DNA fragments encoding SARS-CoV-2 T1076-I1183, T1076-H1159, T1076-N1135, T1076-E1111, T1100-N1135, G1124-H1159, F1148-I1183 and D1168-Q1208 (nucleotide sequences as shown in SEQ ID NO.3 to SEQ ID NO.10) was connected into the pGEX-6P-1-GST tag vector, and the recombinant plasmids with a GST tag at the N-terminus were named S2(T1076-I183), S2(T1076-H1159), S2(T1076-N1135), S2(T1076-E1111), S2(T1100-N1135), S2(G1124-H1159), S2(F1148-I1183) and S2(D1168-Q1208) in sequence.

[0084] Similarly, the DNA fragments encoding SARS-CoV-2 V1133-S1147, T1136-E1150, D1139-D1153, Q1142-F1156, L1145-H1159, P1140-D1153, D1139-L1152, P1140-L152, L1141-L1152, D1139-E1151 and D1139-E1150 (nucleotide sequences such as SEQ ID NO. 11 to SEQ ID NO.21) was connected into the pGEX-6P-1-GST vector, and the recombinant plasmids with a GST tag at the N-terminus were named S2(V1133-S1147), S2(T1136-E1150), S2(D1139-D1153), S2(Q1142-F1156), S2(L1145-H1159), S2(P1140-D1153), S2(D1139-L1152), S2(P1140-L152), S2(L1141-L1152), S2(D1139-E1151) and S2(D1139-E1150).

[0085] The gene sequences encoding the S proteins of SARS-CoV-2, PANG / GD, SARS-CoV, WIV1, and HKU3, corresponding to GenBank numbers MN908947.3, QLR06867.1, AY278554.2, AGZ48828.1, and QND76034.1, were optimized to mammalian cell codons and cloned into the pCAGGS vector through EcoRI and BglⅡ restriction enzyme sites to obtain recombinant plasmids pCAGGS-SARS-CoV-2S, pCAGGS-PANG / GD S, pCAGGS-SARS-CoV S, pCAGGS-WIV1 S, and pCAGGS-HKU3 S. The recombinant plasmids were verified by bacterial liquid PCR identification, double enzyme digestion identification, and plasmid gene sequencing to verify whether the inserted exogenous fragments were completely correct.

[0086] (2) SARS-CoV-2S2 (T1076-Q1208) protein expression and purification

[0087] The constructed recombinant plasmid GST-S2(T1076-Q1208)-folden-His was transformed into E.coli BL21 competent cells, coated with LB solid plates (ampicillin resistance), and cultured in an incubator at 37°C overnight. A single clone was picked and cultured in LB medium (ampicillin resistance) at 37°C for about 2.5 hours until the OD 600is 0.6-0.8. After cooling to 16°C, 0.2mM IPTG was added to induce the culture for 16 hours, the bacterial solution was collected and broken by high pressure, the supernatant was obtained by ultracentrifugation, and the supernatant was combined with the GST tag purification resin equilibrated with protein buffer (20mM Tris, pH 8.0, 150mMNaCl) at 4°C for 2 hours. After the end, the impurities were washed with protein buffer, and the target protein was eluted with elution buffer (20mM Tris, 150mM NaCl, 20mM GSH, pH 8.0). The eluted target protein was collected and finely purified by Superdex 200Increase 10 / 300GL gel filtration chromatography column (GE Healthcare). The results showed that the obtained protein was a multimeric form of the "S2" (T1076-Q1208) recombinant protein ( Figure 1 a).

[0088] PSP protease was added to the above target protein to cleave the N-terminal GST tag of the recombinant protein, and the GST tag protein was removed by multiple reverse hanging, and finally the protein buffer (10mM HEPES, pH 7.5, 150mM NaCl) was used for separation and purification by Superdex200Increase 10 / 300GL to obtain S2 (T1076-Q1208) trimer protein with good uniformity and SDS-PAGE identification purity of 95%. The SARS-CoV-2 S2 (T1076-Q1208) trimer protein with good uniformity in the concentrated peak 1 was used as the antigen for immunizing alpacas.

[0089] The above protein expression and purification methods were used to prepare the S2'(T1076-Q1208) protein with a GST tag at the N-terminus and a series of SARS-CoV-2S2(T1076-Q1208) protein truncations of different lengths: S2(T1076-I183), S2(T1076-H1159), S2(T1076-N1135), S2(T1076-E1111), S2(T1100-N1135), S2(G1124-H1159), S2(F1148-I118 3), S2(D1168-Q1208), S2(V1133-S1147), S2(T1136-E1150), S2(D1139-D1153), S2(Q1142-F1156), S2(L1145-H1159 ), S2(P1140-D1153), S2(D1139-L1152), S2(P1140-L152), S2(L1141-L1152), S2(D1139-E1151) and S2(D1139-E1150).

[0090] Example 2 Construction of SARS-CoV-2S2 (T1076-Q1208)-specific Nanobody Library

[0091] (1) Immunization of animals

[0092] The SARS-CoV-2S2 (T1076-Q1208) trimer protein purified in Example 1 was used as an antigen to immunize alpacas. On day 0 of immunization, alpacas were subcutaneously immunized with 0.5 mg of SARS-CoV-2S2 (T1076-Q1208) trimer protein in the presence of Freund's adjuvant (CFA). On days 21 and 42 of immunization, 0.25 mg of SARS-CoV-2S2 (T1076-Q1208) trimer protein was subcutaneously inoculated in the presence of Freund's incomplete adjuvant (IFA), respectively. On day 49 of immunization, 50 mL of immunized alpaca blood was collected.

[0093] (2) Construction of specific nanoantibody library

[0094] Peripheral blood mononuclear cells were isolated from immunized alpaca blood, and RNA was purified from the mononuclear cells. The purified RNA was reverse transcribed into cDNA and amplified by PCR, and then the VHH fragment was purified from the amplified product and constructed into the commercial pComb3XSS vector. The recombinant vector was electroporated into TG1 competent cells to prepare a phage library, and then a single phage clone was obtained by screening and its initial binding ability with the SARS-CoV-2S2 (T1076-Q1208) antigen was tested.

[0095] (3) Plasmid construction

[0096] 20 nanoantibodies (H6, H8, H15, H17, H23, H27, H36, H49, H58, H68, H84, H85, H88, H93, H102, H145, H147, H177, H180, H184) were selected and synthesized from the SARS-CoV-2S2 (T1076-Q1208) specific nanoantibody library obtained by alpaca immunization, and His tags and translation termination codons were introduced at the C-terminus of the coding gene sequence of the nanoantibody, and then the gene fragments encoding the nanoantibody were cloned into the commercial pNCMO2 vector by homologous recombination using the BamH I and Hind III restriction sites to obtain 20 recombinant plasmids. The recombinant plasmids were verified by bacterial liquid PCR identification, double enzyme digestion identification and plasmid gene sequencing to verify whether the inserted exogenous fragments were completely correct.

[0097] (4) Nanobody expression and purification

[0098] The 20 nanoantibody recombinant plasmids constructed in step (3) were electroporated into Brevibacillus choshinensis SP3 competent cells, coated with LB solid medium (neomycin sulfate resistance) and cultured overnight in an incubator at 37°C. Then, a single colony was picked for amplification culture. After 4 days of expression, the bacterial solution was collected and centrifuged. The supernatant was combined with Ni-TEDNUPharose FF beads (NUPTEC) at 4°C for 2 hours. After completion, the impurities were eluted with a low concentration imidazole buffer (10mM HEPES, pH7.5, 150mM NaCl, 10mM imidazole), and the target protein was eluted with a high concentration imidazole elution solution (10mM HEPES, pH 7.5, 150mM NaCl, 200mM imidazole). The eluted target protein was collected and passed through Superdex TM Fine purification was performed using a 7510 / 300GL gel filtration column (GE Healthcare). Figure 2 As shown, the elution peak of the nanoantibody in gel filtration chromatography is single and symmetrical, indicating that it has good uniformity in the solution, and SDS-PAGE identification shows that the purity of the 20 nanoantibodies is more than 99%.

[0099] Example 3 Screening and identification of neutralizing nanobodies

[0100] (1) ELISA verification of the binding ability of 20 Nanobodies in Example 2 to SARS-CoV-2S2 (T1076-Q1208) antigen

[0101] (1) The recombinant protein S2' (T1076-Q1208) constructed in Example 1 was diluted to a final concentration of 2 μg / mL using a pH 9.6 carbonate buffer solution, and 100 μL / well was added to a 96-well plate for overnight coating at 4°C. (2) After removing the coating solution, the plate was coated with 1×PBST (1×PBS solution with 0.05% Tween 20) Wash 3 times; (3) Add 100 μL of blocking solution containing 5% skim milk (prepared with 1×PBST solution) to each well and block for 1.5 h at room temperature; (4) Remove the blocking solution and wash 3 times with 1×PBST; (5) Allow the nanoantibody to bind for 1.5 h at room temperature: the concentrations are 200 nM and 1000 nM, 100 μL / well, and 3 duplicate wells are set up. The PBS group is a blank control without the addition of nanoantibodies; (6) Remove the supernatant and wash 3 times with 1×PBST; (7) Add HRP-linked anti-His antibody (Proteintech) and bind for 1 h at room temperature; (8) Remove the supernatant and wash 3 times with 1×PBST; (9) TMB (tetramethylbenzidine, Beyotime) color development, 50 μL / well; (10) After the color changes significantly (3-5 min), add 50 μl / well 0.2 M HCl to terminate the color development reaction; (11) Detect OD450 with an enzyme reader nm light absorption value; (12) Calculate the sample absorbance value = sample OD value - blank control OD average value.

[0102] Result analysis: In the ELISA experiment, the coated S2'(T1076-Q1208) antigen has no His tag at the C-terminus, while the nanobody has a His tag at the C-terminus. Therefore, the strength of the OD value represents the ability of the nanobody to bind to the S2'(T1076-Q1208) antigen. The higher the OD value, the stronger the ability of the nanobody to bind to the S2'(T1076-Q1208) antigen. Figure 3 It was shown that 13 nanobodies, such as H8, H17, H23, H49, H58, H68, H84, H85, H88, H93, H145, H177 and H180, could strongly bind to S2'(T1076-Q1208) antigen at a concentration of 1000 nM.

[0103] (2) Flow cytometry verification of the specific binding ability of 20 nanoantibodies to the cell surface SARS-CoV-2S protein

[0104] In order to further verify the binding ability of the nanobody to the complete trimeric S protein, the binding of the nanobody to the complete S protein on the cell surface was detected by flow cytometry.

[0105] HEK-293T cell culture and plasmid transfection: (1) HEK-293T cells were cultured with complete medium (10% FBS + double antibody + DMEM basal medium) until the cell density reached 80% (~18h); (2) Cell transfection: According to the method provided in the transfection reagent manual, the plasmid pCAGGS-SARS-CoV-2S encoding the SARS-CoV-2S protein was transfected into 293T cells using lipo8000 (Biyuntian) transfection reagent.

[0106] The specific operation steps of the flow cytometry experiment are as follows: (1) 2 days after transfection, 293T cells expressing S protein on the membrane surface (referred to as 293T-S) were collected; (2) 4×10 5 293T-S cells were combined with nanoantibodies at room temperature for 1.5 hours, with a final concentration of 200 nM or 1000 nM nanoantibodies, and a PBS negative control group was set up; (3) 1×PBS buffer (containing 0.5% FBS) was centrifuged to remove non-specific binding nanoantibodies; (4) anti-His-PE (Miltenyi) flow cytometry antibody was added and incubated at 4°C for 15 minutes to label the nanoantibodies with His tags; (5) 1×PBS buffer (containing 0.5% FBS) was added and centrifuged to remove non-specific binding flow cytometry antibodies; (6) The proportion of positive cells in the PE channel was detected by flow cytometry. The percentage of PE positive cells represents the percentage of 293T-S cells that have bound nanoantibodies.

[0107] The results are as follows Figure 4 As shown, 8 nanobodies (H17, H49, H58, H68, H93, H145, H177 and H180) specifically bind to 293T-S cells at a concentration of 1000 nM, and these 8 nanobodies can bind to the S2'(T1076-Q1208) antigen in the ELISA experiment; among them, the percentages of nanoantibodies H17, H58, H93 and H145 binding to 293T-S cells at concentrations of 200 nM and 1000 nM have no significant difference, and they are strongly binding nanoantibodies, while the percentages of H49, H68, H177 and H180 binding to 293T-S cells at a concentration of 200 nM are significantly lower than those at a concentration of 1000 nM, and they are weakly binding nanoantibodies, and the remaining 12 antibodies are non-binding nanoantibodies.

[0108] (3) Screening of Nanobodies H17 and H145 by Syncytium Formation Inhibition Experiment

[0109] To further verify the neutralizing activity of the 20 nanoantibodies, a SARS-CoV-2 S protein-mediated syncytium formation inhibition experiment was conducted.

[0110] The specific experimental protocol for inhibition of syncytium formation is as follows: (1) HEK-293T cells were cultured with complete medium (10% FBS + double antibody + DMEM basal medium). When the cell density reached 80% (~18 h), the expression plasmid pCAGGS-SARS-CoV-2S encoding SARS-CoV-2S and the expression plasmid pEGFP-N1 encoding EGFP protein (purchased from Invitrogen) were co-transfected into HEK-293T cells (referred to as 293T-S / EGFP) by Lipo8000 according to the method provided in the transfection reagent manual; (2) 40 h after transfection, 293T-S / EGFP cells were collected by digestion and centrifugation, and then 2.5×10 4 The cells were inoculated into a 96-well plate at a density of 100 cells / well; (3) the nanoantibody was added to each well and mixed evenly, and then incubated at 37°C for 30 min to facilitate the binding of the nanoantibody to the S protein on the cell surface; (4) 5×10 4 HEK-293T cells (293T-ACE2 for short) that stably express ACE2 receptor (NCBI No.: BAB40370.1) were used as receptor cells, and the cells were mixed thoroughly to allow the two cells to fuse evenly; (5) After 6 hours of incubation at 37°C, the area of ​​green fluorescence was observed using a fluorescence microscope (Olympus). The total volume of each well in this system was 150 μL, and 293T-S / EGFP cells, nanoantibodies, and 293T-ACE2 cells were added in equal volumes, with a final concentration of nanoantibodies of 666 nM, and three sub-wells were set up for each. A negative control group (only 293T-S / EGFP cells, referred to as the NC group) and a positive control group (containing 293T-S / EGFP and 293T-ACE2 cells, referred to as the PBS control group, referred to as PC) were set up.

[0111] Experimental principle: The S protein expressed on the surface of 293T-S / EGFP donor cells can specifically bind to cells expressing ACE2 receptors, thereby mediating the fusion of the two, forming a fusion cell with an enlarged area called a syncytium, and EGFP also transfers from 293T-S / EGFP donor cells to fusion cells, and the green fluorescence area increases under the microscope. If the antibody binds to the S protein, it can block the membrane fusion process mediated by the S protein, showing that the formation of the syncytium is inhibited, that is, the green fusion fluorescence area is small. Figure 5 As shown, at this experimental concentration, non-binding antibodies and most weakly binding antibodies can hardly inhibit the formation of syncytia mediated by SARS-CoV-2S protein; among them, binding antibodies H49, H58 and H93 have the ability to slightly inhibit syncytia formation, so there are still many syncytia; while nanoantibodies H17 and H145 have a strong ability to inhibit syncytia formation, and there is almost no formation of fused syncytia, so H17 and H145 are strong neutralizing nanoantibodies.

[0112] Example 4 In vitro test to verify the neutralizing activity of H17 and H145 against SARS-CoV-2 and its variants

[0113] (1) H17 and H145 inhibit SARS-CoV-2 S protein-mediated membrane fusion

[0114] The same experimental method as the syncytium formation inhibition experiment in Example 3 was used to further explore the inhibitory effects of nanoantibodies H17 and H145 at multiple dilution concentrations on the SARS-CoV-2S protein-mediated membrane fusion process.

[0115] like Figure 6 As shown in the figure, with the increase of the concentration of H17 and H145 nanoantibodies, their ability to inhibit syncytium formation gradually increased until saturation. The half-inhibitory concentrations IC50 of H17 and H145 were calculated by Graphpad 8.0 software, which were 12.8nM and 21.7nM, respectively, indicating that H17 and H145 can exert antiviral neutralizing activity by inhibiting the membrane fusion process mediated by SARS-CoV-2S protein, and have a strong inhibitory effect on membrane fusion.

[0116] (2) Pseudovirus neutralization assay to detect the inhibitory activity of H17 and H145 against the original strain of SARS-CoV-2

[0117] Subsequently, the neutralizing activity of nanoantibodies H17 and H145 against the original strain of SARS-CoV-2 was investigated through pseudovirus neutralization experiments.

[0118] The specific protocol for the pseudovirus neutralization experiment is as follows: (1) 0.1 mg / ml L-poly-lysine was coated on a 96-well cell culture plate. After overnight coating, the plate was washed once with ddH2O; (2) 293T-ACE2 cells were cultured at 1×10 4The cells were inoculated into a 96-well plate at a density of 100 / well and grown in a cell culture incubator at 37°C for 6 h. (3) The nanoantibody and SARS-CoV-2 original strain pseudovirus (purchased from Genomeditech) were diluted with DMEM basal culture medium, and the diluted nanoantibody and SARS-CoV-2 original strain pseudovirus were mixed in equal volumes and incubated in a 37°C incubator for 1 h to allow the nanoantibody to fully bind to the SARS-CoV-2S protein on the surface of the pseudovirus to obtain a pseudovirus / nanoantibody mixture. (4) The culture medium of 293T-ACE2 cells was discarded, and the pseudovirus / nanoantibody mixture was added to simulate the virus infection process, and a PC group without a nanoantibody group was set up. (5) After 24 h of infection, the culture medium containing fresh complete culture medium (10% FBS + double antibody + DMEM basal culture medium) was replaced. (6) After 48 h of infection, the luciferase activity in 293T-ACE2 cells was measured using the One-LumiTMII firefly luciferase assay kit (Beyotime). The higher the luciferase reading, the more virus infection value. (7) Calculate the pseudovirus neutralization activity = (PC value - experimental group value) / PC value, where the PC well represents the pseudovirus infection value without the addition of nanoantibodies. The larger the neutralization activity value, the stronger the ability of the nanoantibody to inhibit pseudovirus infection; (9) Use GraphPad Prism 8 to draw the neutralization activity curve and calculate the half inhibitory concentration (IC 50 )value.

[0119] The results are as follows Figure 7 As shown: the non-neutralizing nanoantibody H6 (amino acid sequence as shown in SEQ ID NO.30, nucleotide sequence as shown in SEQ ID NO.33) has no inhibitory activity, and the IC50 values ​​of the neutralizing nanoantibodies H17 and H145 are 58.8nM and 70.8nM, respectively, indicating that H17 and H145 have strong inhibitory activity against the original strain of SARS-CoV-2.

[0120] (3) Pseudovirus neutralization assay to detect the inhibitory activity of H17 and H145 against SARS-CoV-2 variants

[0121] The neutralization activity of H17 and H145 against SARS-CoV-2 variants Omicron (BA.1, BA.2, BA.2.12.1, BA.4 / 5), Beta (B.1.351), Mu (B.1.621), Kappa (B.1.617.1), and Delta (B.1.617.2) pseudoviruses (purchased from Genomeditech) was verified by pseudovirus neutralization experiments. The pseudovirus neutralization experiment protocol was the same as step (2).

[0122] The results are as follows Figure 8As shown, the results suggest that both nanoantibodies H17 and H145 can effectively neutralize SARS-CoV-2 variant pseudoviruses, especially against the Omicron variant, and both show stronger inhibitory activity than other variants. In addition, both H17 and H145 show better inhibitory activity against the currently popular Omicron sublineage variants than the original strains. It can be seen that nanoantibodies H17 and H145 have broad-spectrum neutralizing activity against SARS-CoV-2 variants.

[0123] Table 1 IC of H17 and H145 against SARS-CoV-2 variant pseudovirus 50 value

[0124]

[0125] Example 5 Identification of antigen binding epitopes of nanobodies H17 and H145 and conservation analysis in different variants

[0126] (1) Identification of antigen-binding epitopes of nanobodies H17 and H145

[0127] In order to identify the antigen-binding epitopes of nanoantibodies H17 and H145, the S2 (T1076-Q1208) protein constructed in Example 1 and its series of truncated proteins S2 (T1076-I183), S2 (T1076-H1159), S2 (T1076-N1135), S2 (T1076-E1111), S2 (T1100-N1135), S2 (G1124-H1159), S2 (F1148-I1183), S2 (D1168-Q1208) were used to screen and identify the antigen-binding epitopes of H17 and H145 by WB, ELISA and biofilm interferometry (BLI) experiments.

[0128] The WB experimental operation steps are as follows: (1) 0.1ug / well was loaded on 15% SDS-PAGE gel, and the samples were a series of SARS-CoV-2S2 (T1076-Q1208) antigen protein truncations with different truncation lengths; (2) Electrophoresis: 90mAu×20min first and then adjusted to about 160mAu×30min; (3) Transfer: 400mAu×90min; (4) Blocking with TBST solution containing 5% skim milk powder at room temperature for 1.5h; (5) Washing 3 times with 1×PBST; (6) Primary antibody incubation: Nano antibody H17 or H145 (1μg / ml) was incubated at room temperature for 1h; (7) Washing 3 times with 1×PBST to remove non-specific binding antibodies; (8) Secondary antibody incubation: HRP direct-linked anti-His antibody (Proteintech) was incubated at room temperature for 1h; (9) Washing 3 times with 1×PBST; (10) Exposure after ECL luminescence solution. If the nanobody (with His tag) binds to the antigen sample (without His tag), the intensity of exposure detected by WB represents the binding of the His-tagged nanobody to the antigen. The ELISA experimental operation scheme is the same as above, and the coating solution contains S2 (without His tag) protein with different truncated lengths with a GST tag at the N-terminus, and the primary antibody is still the nanobody H17 or H145. The BLI experimental operation steps are as follows: (1) The nanoantibodies H17 and H145 were mixed with the biotinylation reagent at a molar ratio of 1:1 and combined at room temperature for 40 minutes. The biotinylated target proteins H17 and H145 were collected using a balanced desalting column; (2) The biotinylated target proteins H17 and H145 were fixed on the SA sensor (Sartorius) with a solidification height of 2 nm; (3) A series of SARS-CoV-2S2 (T1076-Q1208) antigen protein truncations (200 nM) with different truncation lengths were reacted with the solidified material on the SA sensor, with a binding time of 90 s, a dissociation time of 180 s, and a frequency of 2 Hz; (4) The kinetic parameters were analyzed using the ForteBio DataAnalysis 12.0 program software, and the graphs were drawn using GraphPad Prism 8.0. WB experiments are used to detect whether H17 and H145 bind to the linear epitope of the antigen, ELISA experiments further verify whether H17 and H145 bind to the antigen epitope, and BLI experiments are more sensitive to verify whether the antigen binds to H17 or H145.

[0129] like Fig. 9ad, the results of WB, ELISA and BLI experiments were consistent, indicating that H17 and H145 could specifically bind to S2'(T1076-Q1208), S2(T1076-I183), S2(T1076-H1159) and S2(G1124-H1159) antigens. According to the analysis of the amino acid length of the antigen epitope, H17 and H145 may bind to the antigen epitope S2(V1133-H1159).

[0130] Therefore, five different SARS-CoV-2 S2 (T1076-Q1208) antigen protein truncations, S2 (V1133-S1147), S2 (T1136-E1150), S2 (D1139-D1153), S2 (Q1142-F1156), and S2 (L1145-H1159), were designed based on the S2 (V1133-H1159) antigen epitope by epitope overlap, such as Fig. 9 As shown in eh, the results of WB, ELISA and BLI experiments were consistent, indicating that both H17 and H145 could bind to the linear epitope of S2 (D1139-D1153) antigen.

[0131] In order to further shorten the length of the binding epitope amino acids, a series of SARS-CoV-2S2 (T1076-Q1208) antigen protein truncations S2 (P1140-D1153), S2 (D1139-L1152), S2 (P1140-L152), S2 (L1141-L1152), S2 (D1139-E1151) and S2 (D1139-E1150) were designed for the S2 (D1139-D1153) antigen. Fig. 9 As shown in Figure 11, the results of WB, ELISA and BLI experiments are also consistent. The results show that the shortest antigen epitope amino acid sequence bound by H17 and H145 is the same, both of which are S2 (D1139-L1152). Although the WB results all indicate that H17 and H145 can bind to the antigen linear epitope S2 (D1139-E1151), the binding ability is significantly reduced compared to S2 (D1139-L1152). And the ELISA results show that H17 cannot bind to S2 (D1139-E1151). Although H145 has a certain binding ability with S2 (D1139-E1151), the ELISA results indicate that the EC50 value of binding to S2 (D1139-L1152) is significantly increased by 100 times compared to S2 (D1139-E1151), indicating that the antigen epitope L1152 amino acid plays an important role in the binding with H17 or H145. It can be seen that the shortest antigen binding epitopes of nanoantibodies H17 and H145 are both SARS-CoV-2D 1139 PLQPELDSFKEEL1152 Through amino acid sequence analysis, it was found that amino acids D1139-L1152 are located in the stem helix (SH) region of the SARS-CoV-2S protein.

[0132] (2) Conservative analysis of the antigen-binding epitopes of nanoantibodies H17 and H145 in different variants

[0133] After determining the antigen-binding epitopes of nanoantibodies H17 and H145, in order to analyze the reasons for the broad-spectrum neutralization activity of H17 and H145 pan-variants from the perspective of sequence and structure, the amino acid sequences of the main variants of SARS-CoV-2 in the antigen-binding epitopes were analyzed by sequence comparison. Fig.10 Sequence comparison results suggest that nanoantibodies H17 and H145 bind to the antigen-binding epitope D in the stem-helix structure. 1139 PLQPELDSFKEEL 1152 The amino acid sequences are highly conserved in all SARS-CoV-2 variants named by the WHO, thus verifying the reason why the nanoantibodies H17 and H145 have pan-variant broad-spectrum neutralizing activity from a sequence and structural perspective.

[0134] Example 6 Identification of broad-spectrum neutralizing activity of H17 and H145

[0135] (1) H17 and H145 epitopes are highly conserved in Sabeivirus

[0136] To further explore the broad-spectrum neutralizing activity of H17 and H145, we first compared the differences in the amino acid sequences of antigen-binding epitopes in Sabei viruses such as SARS-CoV (highly contagious and pathogenic), PANG / GD, WIV1, and HKU3 (which can cause zoonotic diseases). Fig.11 a, Sequence comparison suggests that the antigen binding epitope D in the stem helix region of nanoantibodies H17 and H145 1139 PLQPELDSFKEEL 1152 The amino acid sequence is highly conserved among Sabeiviruses such as SARS-CoV-2, PANG / GD, SARS-CoV, WIV1, and HKU3, suggesting that H17 and H145 can exert broad-spectrum neutralizing activity by binding to Sabeivirus stem-helix antigen epitopes.

[0137] (2) Verification of the ability of H17 and H145 to bind to the intact Sabei virus S protein on the cell surface

[0138] In order to verify the above hypothesis, the binding ability of nanoantibodies H17 and H145 to the complete S protein of Sabei virus on the cell surface was detected by flow cytometry. The experimental scheme for detecting the binding affinity of cell surface S protein and nanoantibody by flow cytometry was the same as that in Example 3, and the plasmid carrying the encoding S protein was adjusted to pCAGGS-SARS-CoV S, pCAGGS-PANG / GD S, pCAGGS-WIV1 S or pCAGGS-HKU3 S.

[0139] like Fig.11 b. The results suggest that the binding affinity of H17 and H145 to the surface S protein of PANG / GD, SARS-CoV, WIV1 and HKU3 cells is at the nanomolar level. The binding EC50 values ​​of H17 are 1.23nM, 1.86nM, 3.08nM and 1.70nM, respectively, and the binding EC50 values ​​of H145 are 0.77nM, 1.32nM, 2.62nM and 1.28nM, respectively. It can be seen that H17 and H145 have high affinity to the S protein of Sabei virus, and the binding affinity is not significantly different from the binding affinity value of SARS-CoV-2S protein.

[0140] (3) Pseudovirus neutralization experiments verify the neutralization activity of H17 and H145 against Sabei virus

[0141] The neutralization activity of H17 and H145 against Sabae virus PANG / GD, SARS-CoV, WIV1 and HKU3 (purchased from Genomeditech) was further verified by pseudovirus neutralization experiments. The pseudovirus neutralization experiments refer to Example 4. Fig.11 As shown in cd, for PANG / GD, SARS-CoV, WIV1 and HKU3 pseudoviruses, H17 and H145 both have excellent pseudovirus neutralization activity, and the IC50 values ​​of H17 are 0.65nM, 27.67nM, 13.75nM and 7.73nM, respectively; the IC50 values ​​of H145 are 2.65nM, 21.64nM, 16.57nM and 7.75nM, respectively. The results show that the nanoantibodies H17 and H145 have broad-spectrum Sabeivirus neutralization activity, and the neutralization activity is significantly better than its neutralization activity against SARS-CoV-2.

[0142] Example 7 The binding of neutralizing nanobodies H17 and H145 to antigenic epitopes is not affected by acidic pH

[0143] SARS-CoV-2 enters host cells mainly through two pathways: fusion of the virus with the cell surface membrane or the endosomal pathway. During the fusion process of the endosomal pathway, the virus undergoes a microenvironment change with a lower pH, from the neutral environment of the cytoplasm (pH 7.4) to the acidic environment of the endosome (pH 5.4). In order to explore whether pH changes affect the binding ability of nanoantibodies H17 and H145 to the antigenic epitope of SARS-CoV-2S protein, the affinity of H17 and H145 to S2" (T1076-Q1208) protein was explored by BLI experiment. BLI experimental steps refer to Example 5. The present invention respectively determines the affinity under the conditions of protein buffer at pH 7.4 (HEPES 10mM, NaCl 150mM, Tween 20 0.05% V / V, pH 7.4), 6.0 (MES 10mM, NaCl 150mM, Tween 20 0.05% V / V, pH 6.0) and 5.4 (MES 10mM, NaCl 150mM, Tween 20 0.05% V / V, pH 5.4). Fig.12 As shown, at pH 7.4, 6.0 and 5.4, nanoantibodies H17 and H145 can bind to S2" (T1076-Q1208) antigen with high affinity. Among them, the binding affinity values ​​of H17 are 0.330nM, 0.351nM and 0.607nM, respectively, and the binding affinity values ​​of H145 are 0.223nM, 0.229nM and 0.314nM, respectively.

[0144] The results show that in the pH range of 6.0-7.4, there is no significant change in the binding of H17 and H145 to the antigenic epitope; and the affinity values ​​at pH 7.4 are 1.83 times and 1.40 times of the pH 5.4 values, respectively. It can be seen that the binding of nanoantibodies H17 and H145 to the antigenic epitope is almost unaffected by the decrease in pH (from 7.4 to 5.4). At present, the reported neutralizing antibody S2P6 targeting the stem helix epitope shows pH dependence in its binding to the antigenic epitope, and the affinity values ​​of its Fab and IgG forms to SARS-CoV-2pre-S at pH 7.4 are 6.47 times and 5.75 times that of pH 5.4. Therefore, when the virus infects cells through the endosome pathway, H17 and H145 are less susceptible to the decrease in pH, suggesting that nanoantibodies may have better effects than S2P6 antibodies under this condition.

[0145] Example 8 Flow cytometry experiments verify that H17 and H145 bind to the S protein in the pre-fusion conformation

[0146] The recombinant plasmid pCAGGS-SARS-CoV-2S constructed in Example 1 was used as a template, and primers were designed by mutation sites to mutate SARS-CoV-2S protein at four amino acid sites K986P, V987P, S383C and D985C, with the aim of stabilizing the S protein in a pre-fusion conformation to obtain a mutant plasmid pCAGGS-SARS-CoV-2pre-fusion S. First, using the SARS-CoV-2S gene as a template, three DNA fragments were amplified using mutation primers F1 / R1, F2 / R2, and F3 / R3, respectively, with the 1st to 389th amino acids being the first fragment; the 377th to 962nd amino acids being the second fragment; and the 950th to the last amino acid being the third fragment (wherein the overlapping part is the homology arm). The three recovered DNA fragments were recombined into the pCAGGS vector by homologous recombination. The recombinant plasmid was verified by bacterial liquid PCR identification, plasmid gene sequencing, and the like to verify whether the inserted exogenous fragments were completely correct.

[0147] Table 2 Mutation primers

[0148] name Primer sequence (5'-3') F1 TTCAAGTGTTACGGCGTGTGCCCCACCAAGCTGAACGACC R1 GGTCGTTCAGCTTGGTGGGGCACACGCCGTAACACTTGAA F2 ACACAGACAAACTCCCCAAGCGGAGCCGGATCCGTGGCCTCCCAGTCC R2 GGACTGGGAGGCCACCGGATCCGGCTCCGCTGGGGGAGTTTGTCTGTGT F3 GATATCCTGAGCCGGCTGTGCCCACCAGAGGCTGAAGTGCAGATT R3 AATCTGCACTTCAGCCTCTGGTGGGCACAGCCGGCTCAGGATATC

[0149] Structural analysis showed that the stem helix regions of the H17 and H145 antigen-binding epitopes were exposed in the pre-fusion structure of SARS-CoV-2. Therefore, flow cytometry experiments were used to detect the binding of H17 and H145 nanoantibodies to the wild-type S protein expressed on the cell surface and the S protein in a fixed pre-fusion conformation. The steps of the flow cytometry experiment were referred to Example 3. During cell transfection, the plasmid pCAGGS-SARS-CoV-2S was adjusted to the mutant plasmid pCAGGS-SARS-CoV-2pre-fusion S.

[0150] The results are as follows Fig.13 As shown, the results suggest that both H17 and H145 can bind to the wild-type S protein (EC50 values ​​are 1.23nM and 0.77nM, respectively) or the S protein in the pre-fusion conformation (EC50 values ​​are 0.97nM and 1.37nM, respectively) with high affinity, and there is no significant difference in binding affinity, both of which are in the nanomolar range.

[0151] Example 9 Analysis of the window period during which nanoantibodies H17 and H145 exert membrane fusion inhibition effects

[0152] Nb20 and R150 are reported neutralizing nanobodies targeting the RBD region. The surface plasmon resonance experiment measured their binding affinities to RBD to be approximately 67pM and 10pM, respectively, and both can compete with ACE2 for binding to the RBD epitope [14,15]. Given that the stem helix region of the H17 and H145 antigen-binding epitopes is located in the S2 subunit and does not compete with ACE2 for binding to RBD, the present invention uses a SARS-CoV-2S protein-mediated syncytium formation inhibition experiment to explore whether the ability of nanobodies to inhibit syncytium formation at different membrane fusion stages is different, that is, a head-to-head comparison study of the window period of inhibitory activity.

[0153] The overall scheme of the syncytium formation inhibition experiment is the same as that of Example 3, except that the time of adding nano antibodies is adjusted to three different time points: time point 1—nano antibodies are pre-combined with 293T-S / EGFP cells for 1 hour, and then mixed and incubated with 293T-ACE2 cells, marked as Pre in the figure, to analogize the window mode of antibody inhibitory activity before free virus adheres to the target cell surface; time point 2—293T-S / EGFP cells are mixed and incubated with nano antibodies while adding 293T-ACE2 cells, marked as Co in the figure, to analogize the window mode of antibody inhibitory activity while virus adheres to the target cell surface; time point 3—293T-S / EGFP cells are mixed and incubated with 293T-ACE2 cells for 1 hour, and then nano antibodies are added, marked as Post in the figure, to analogize the window mode of antibody inhibitory activity after virus adheres to the target cell surface. The final concentration of the nano antibodies used in this experiment in the cell system was 1 μM.

[0154] like Fig.14As shown, the non-neutralizing nanoantibody H6 could not inhibit the formation of syncytia in the three window modes of Pre, Co and Post, which was in line with expectations; the neutralizing nanoantibodies H17, H145, R150 and Nb20 could significantly inhibit the formation of syncytia in the Pre window mode, and their inhibition rates were close to 100%; while in the window mode of Co co-incubation, the inhibition ability of H17 and H145 was not significantly different from that in the Pre mode, but the ability of R150 and Nb20 to inhibit syncytia formation had decreased, and the average inhibition rates decreased to 82.0% and 89.5%, respectively; and in the Post window mode, although the ability of H17 and H145 to inhibit syncytia formation also decreased, their inhibition rates were still maintained at 80.1% and 76.9%, while the ability of R150 and Nb20 to inhibit syncytia formation was significantly reduced, and the average inhibition rates decreased to 27.5% and 42.2%, respectively. The above results show that although the affinity of nanoantibodies H17 and H145 to SARS-CoV-2S protein is lower than that of nanoantibodies Nb20 and R150, the inhibitory activity of nanoantibodies H17 and H145 targeting the stem helix epitope of the membrane fusion subunit is better than that of nanoantibodies R150 and Nb20 targeting RBD at the same time or after SARS-CoV-2 adheres to the surface of the target cell, especially after the virus adheres to the surface of the target cell, the difference is more obvious. It can be seen that the effective window period of nanoantibodies H17 and H145 targeting the stem helix epitope of SARS-CoV-2 to inhibit syncytium formation is significantly better than that of nanoantibodies R150 and Nb20 that compete with ACE2 for binding to the RBD epitope, indicating that neutralizing nanoantibodies such as H17 and H145 targeting membrane fusion subunits may play a better role in the treatment of new crown infection.

[0155] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A SARS-CoV-2S2 protein epitope peptide, characterized in that: The amino acid sequence of the epitope peptide is shown in SEQ ID NO.

28.

2. A gene encoding the SARS-CoV-2S2 protein epitope peptide according to claim 1.

3. The gene according to claim 2, characterized in that The nucleotide sequence of the gene is shown in SEQ ID NO.

34.

4. An expression vector containing a gene encoding the SARS-CoV-2S2 protein epitope peptide according to claim 1.

5. A host cell containing a gene encoding the SARS-CoV-2S2 protein epitope peptide according to claim 1.

6. A broad-spectrum vaccine against coronavirus, characterized in that: The vaccine contains the SARS-CoV-2S2 protein epitope peptide described in claim 1, or the gene described in claim 2 or 3, or the expression vector described in claim 5, or the host cell described in claim 6.

7. The broad-spectrum vaccine according to claim 6, characterized in that The broad-spectrum vaccine includes an immunologically acceptable carrier or adjuvant.

8. Use of the SARS-CoV-2S2 protein epitope peptide according to claim 1, or the gene according to claim 2 or 3, or the expression vector according to claim 5, or the host cell according to claim 6 in the preparation of a broad-spectrum coronavirus vaccine, an antigen detection kit, a SARS-CoV-2S2 protein monoclonal antibody or a bispecific antibody.

Citation Information

Patent Citations

  • High affinity nanoantibodies of SARS-CoV-2 alpha, gamma, delta and o mutants camel source

    CN114805563A

  • Preparation and application of broad-spectrum neutralizing monoclonal antibody for resisting new coronavirus

    CN115521375A

  • Antigenic peptides of SARS coronavirus and uses thereof

    US20060110803A1